FRANKLIN LAKES, N.J., Aug. 15, 2011 /PRNewswire/ — BD Medical,
a segment of BD (Becton, Dickinson and Company), today announced
the launch of the BD Emerald™ Syringe portfolio designed to
meet emerging needs in medication delivery while addressing
environmental impact by reducing material. The BD Emerald Syringe
portfolio includes the BD Emerald™ Conventional Syringe for
general medication preparation and delivery, the BD Emerald
Saf-T™ Syringe with a shielding mechanism to protect against
needlesticks and the BD Emerald PRO™ Reuse Prevention Syringe
featuring a passive locking system to prevent reuse.
The BD Emerald product family is designed sustainably with input
from clinicians around the world. The product family is also
supported by the Company’s long-standing history and commitment to
developing first-class injection devices supported by clinical
education programs to improve the delivery of healthcare. The BD
Emerald Syringes will be manufactured at facilities in Spain, India
and Brazil, utilizing sustainable manufacturing practices,
including 100 percent renewable electricity for production where
available. The syringes meet the International Organization and
Standardization requirements, and satisfy local registration
standards.
“BD recognizes that human health and a healthy environment
are inseparable,” said Bill Kozy, Executive Vice President,
BD. “We are committed to responsible environmental
stewardship in our business conduct. The BD Emerald Syringes meet
our highest standards for product quality while also reducing
environmental impact by using sustainable operations practices and
less material.”
The BD Emerald Syringe family offers features to prevent the
spread of infection, address environmental impact, address clinical
needs and meet quality standards around the world:
- BD Emerald Saf-T Syringe is designed to address the needs
of‘/>”/>
